Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Nefrología (Madr.) ; 34(2): 216-222, mar.-abr. 2014. ilus, tab
Artículo en Español | IBECS | ID: ibc-124779

RESUMEN

Antecedentes: No hay suficiente evidencia sobre la frecuencia de rechazo agudo y la función del injerto en los pacientes con retiro temprano de esteroides (RTE). El objetivo del presente estudio es comparar el efecto del RTE sobre la tasa de filtrado glomerular (TFG), la supervivencia/rechazo del injerto en receptores de una cohorte de tratados con tacrolimus/mofetil micofenolato, comparada con un grupo control. Material y métodos: Cohorte retrospectiva en 60 receptores de bajo riesgo inmunológico entre diciembre de 2005 y julio de 2010. Cohorte del estudio (C-RTE; N = 32), el RTE se hizo el 5o día mientras recibían tacrolimus/mofetil micofenolato. La cohorte control (C-C, N = 28) recibió prednisona/tacrolimus/mofetil micofenolato. Las variables clínicas, bioquímicas e histológicas fueron evaluadas al inicio del estudio, y a los 3, 6 y 12 meses de seguimiento. Se utilizó Kaplan-Meier y el modelo de riesgos proporcionales de Cox para evaluar la supervivencia. Las comparaciones entre cohortes fueron hechas por la t de Student y χ2. Resultados: Durante el seguimiento, la C-C muestra presión sanguínea significativamente mayor tanto sistólica (125 ± 10 frente a 114 ± 8) como diastólica (81 ± 8 frente a 72 ± 7), glucosa sérica (96 ± 13 frente a 86 ± 10), triglicéridos (177 ± 61 frente a 129 ± 34), colesterol total (183 ± 43 frente a 148 ± 34) y colesterol LDL (100 ± 22 frente a 87 ± 25). La C-C presentó una mayor proporción de uso de antihipertensivos (57 frente a 13 %) y de estatinas (27 frente a 9 %). La TFGe fue mejor en la C-RTE que en la C-C (85,4 ± 20,6 frente a 70,6 ± 17,0, p = 0,004). La frecuencia de rechazo agudo fue menor en la C-RTE. Conclusiones: La supervivencia del injerto, la TFG, la tasa de rechazo agudo y el perfil metabólico fueron mejores en la C-RTE que en la C-C (AU)


Background: Acute rejection and graft function have not been completely clarified in early-steroid-withdrawal (ESW) patients. The objective of this study was to compare the effect of early steroid withdrawal on GFR, graft survival/rejection in recipients in a cohort treated with tacrolimus/mycophenolate mofetil compared to a control cohort. Material and method: Retrospective cohort, in 60 low immunological risk recipients between December 2005 and July 2010. Study cohort (ESW-C N=32), steroid withdrawal was carried out after 5 days, while they were receiving tacrolimus/mycophenolate mofetil. The control cohort (C-C, N=28) received prednisone/tacrolimus/mycophenolate mofetil. Clinical, biochemical and histological variables were assessed at baseline and after 3, 6, and 12 months of follow-up. Kaplan-Meier and the Cox proportional hazards model were used to assess survival. Comparisons between cohorts were carried out by the Student's t and χ2 tests. Results: At follow-up, C-C displayed significantly higher systolic (125±10 vs. 114±8) and diastolic (81±8 vs. 72±7) blood pressure, serum glucose (96±13 vs. 86±10), triglycerides (177±61 vs. 129±34), total (183±43 vs. 148±34) and LDL-cholesterol (100±22 vs. 87±25). C-C had a higher proportion of antihypertensive (57 vs. 13%), and statins (27 vs. 9%) use. eGFR was better in ESW-C than in C-C (85.4±20.6 vs. 70.6±17.0, p=.004). AR frequency was lower in ESW-C. Conclusions: Graft survival, GFR, AR rate and metabolic profile were better in the ESW-C than in C-C (AU)


Asunto(s)
Humanos , Trasplante de Riñón , Inmunosupresores/uso terapéutico , Rechazo de Injerto/prevención & control , Esteroides/administración & dosificación , Tacrolimus/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Ácido Micofenólico/uso terapéutico , Enfermedad Injerto contra Huésped/tratamiento farmacológico
2.
Nefrologia ; 34(2): 216-22, 2014.
Artículo en Inglés, Español | MEDLINE | ID: mdl-24658197

RESUMEN

BACKGROUND: Acute rejection and graft function have not been completely clarified in early-steroid-withdrawal (ESW) patients. The objective of this study was to compare the effect of early steroid withdrawal on GFR, graft survival/rejection in recipients in a cohort treated with tacrolimus/mycophenolate mofetil compared to a control cohort. MATERIAL AND METHOD: Retrospective cohort, in 60 low immunological risk recipients between December 2005 and July 2010. Study cohort (ESW-C N=32), steroid withdrawal was carried out after 5 days, while they were receiving tacrolimus/mycophenolate mofetil. The control cohort (C-C, N=28) received prednisone/tacrolimus/mycophenolate mofetil. Clinical, biochemical and histological variables were assessed at baseline and after 3, 6, and 12 months of follow-up. Kaplan-Meier and the Cox proportional hazards model were used to assess survival. Comparisons between cohorts were carried out by the Student's t and c2 tests. RESULTS: At follow-up, C-C displayed significantly higher systolic (125 ± 10 vs. 114 ± 8) and diastolic (81 ± 8 vs. 72 ± 7) blood pressure, serum glucose (96 ± 13 vs. 86 ± 10), triglycerides (177 ± 61 vs. 129 ± 34), total (183 ± 43 vs. 148 ± 34) and LDL-cholesterol (100 ± 22 vs. 87 ± 25). C-C had a higher proportion of antihypertensive (57 vs. 13%), and statins (27 vs. 9%) use. eGFR was better in ESW-C than in C-C (85.4 ± 20.6 vs. 70.6 ± 17.0, p=.004). AR frequency was lower in ESW-C. CONCLUSIONS: Graft survival, GFR, AR rate and metabolic profile were better in the ESW-C than in C-C.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Glucocorticoides , Inmunosupresores/uso terapéutico , Trasplante de Riñón , Ácido Micofenólico/análogos & derivados , Prednisona , Proteínas Recombinantes de Fusión/uso terapéutico , Tacrolimus/uso terapéutico , Adulto , Basiliximab , Estudios de Cohortes , Quimioterapia Combinada , Femenino , Tasa de Filtración Glomerular/fisiología , Glucocorticoides/uso terapéutico , Rechazo de Injerto/epidemiología , Supervivencia de Injerto , Humanos , Masculino , Ácido Micofenólico/uso terapéutico , Prednisona/uso terapéutico , Estudios Retrospectivos , Factores de Tiempo , Privación de Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA